The reaffirmation of a Buy rating and a significant price target of $20 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on Aprea Therapeutics' stock price. The analyst's endorsement serves as a strong signal of the company's potential value and growth prospects.